GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » Blackrock Health Sciences Trust (NYSE:BME) » Definitions » Growth Rank

Blackrock Health Sciences Trust (Blackrock Health Sciences Trust) Growth Rank : 0 (As of Jun. 10, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Blackrock Health Sciences Trust Growth Rank?

Blackrock Health Sciences Trust has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.


Blackrock Health Sciences Trust Growth Rank Related Terms

Thank you for viewing the detailed overview of Blackrock Health Sciences Trust's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Blackrock Health Sciences Trust (Blackrock Health Sciences Trust) Business Description

Traded in Other Exchanges
N/A
Address
100 Bellevue Parkway, Wilmington, DE, USA, 19809
Blackrock Health Sciences Trust has an investment objective to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Fund invests 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives.
Executives
Arthur Philip Steinmetz director 50 HUDSON YARDS, NEW YORK NY 10001
Aaron David Wasserman officer: Chief Compliance Officer 50 HUDSON YARDS, NEW YORK NY 10001
Lorenzo Flores director 2100 LOGIC DRIVE, SAN JOSE CA 95124
James Phillip Holloman director P.O. BOX 625737, 6800 CINTAS BOULEVARD, CINCINNATI OH 45262
Stayce D. Harris director 1999 S. BASCOM AVE., SUITE 700, CAMPBELL CA 95008
Trent Walker officer: Chief Financial Officer C/O PIMCO, 650 NEWPORT CENTER DRIVE, NEWPORT BEACH CA 92660
Xiang Liu other: Portfolio Manager 55 EAST 52ND STREET, NEW YORK NY 10055
Jeffrey Gene Lee other: Portfolio Manager 55 EAST 52ND STREET, NEW YORK NY 10055
Kyle Mcclements other: Portfolio Manager 100 BELLEVUE PARKWAY, WILMINGTON DE 19809
Christopher Accettella other: Portfolio Manager 100 BELLEVUE PARKWAY, WILMINGTON DE 19809
H Erin Xie other: Portfolio Manager 100 BELLEVUE PARKWAY, WILMINGTON DE 19809
Cynthia Egan director 7117 BELLONA AVENUE, BALTIMORE MD 21212
Robert W Fairbairn director 55 EAST 52ND STREET, NEW YORK NY 10055
Catherine A. Lynch director 55 EAST 52ND STREET, NEW YORK NY 10055
Jonathan Diorio officer: Vice President 55 EAST 52ND STREET, NEW YORK NY 10055